Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ziopharm Oncology has started patient dosing in an open-label, multi-center, dose-escalation, single-arm Phase 1 trial for evaluating ZIN ATI-001 as a treatment for advanced melanoma.
Subscribe to our email newsletter
The trial aims to investigate the tolerability and safety of intratumoral injections of ZIN ATI-001 (Ad-RTS-IL-12 or INXN-2001).
Mary Crowley Medical Research Center executive medical director John Nemunaitis said ZIN ATI-001 demonstrates the ability to engineer complex, controllable transgenes whose properties cannot be reproduced through traditional therapeutic approaches.